USPTO Examiner MURESAN ANA Z - Art Unit 1622

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
172536394-(P-TRIFLUOROMETHYLBENZYL)-3-FLUORO-1,2,4-TRIPHENYLAMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOFDecember 2020December 2021Allow1211YesNo
17123004METHOD FOR OXIDIZING A 1,1,-BIS-(3,4-DIMETHYLPHENYL)-ALKANE TO 3,3',4,4'-BENZOPHENONE TETRACARBOXYLIC ACIDDecember 2020March 2023Allow2701NoNo
17113248MIXTURES OF CANNABINOID COMPOUNDS, AND PRODUCTION AND USE THEREOFDecember 2020January 2024Allow3711NoNo
17111688DIISOCYANATE COMPOSITION, PREPARATION METHOD THEREOF AND OPTICAL MATERIAL USING SAMEDecember 2020March 2024Allow4022YesNo
17055129PREPARATION OF ZINC LINOLENATE, AND APPLICATION OF ZINC LINOLENATE IN PREPARING ANTI-HELICOBACTER PYLORI DRUGNovember 2020August 2021Allow901YesNo
17055124VINYLSULFONIC ANHYDRIDE, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING VINYLSULFONYL FLUORIDENovember 2020March 2023Allow2811YesNo
17054435OPTIMIZATION OF 2-EH PRODUCT RECOVERY SYSTEM USING PROCESS INTENSIFICATIONNovember 2020September 2021Allow1010NoNo
17090033TRISODIUM SACUBITRIL VALSARTAN AND PROCESS FOR ITS PREPARATIONNovember 2020November 2022Allow2510YesNo
17050925METHOD FOR PREPARING 4,4'-DIHYDROXY-[1,1'-BIPHENYL-3,3'-DICARBOXYLIC ACID]October 2020August 2022Allow2110NoNo
17071013PROCESSES FOR PREPARING A 2-(1,2,2-TRIMETHYL-3-CYCLOPENTENYL)-2-OXOETHYL CARBOXYLATE COMPOUND AND HYDROXYMETHYL 1,2,2-TRIMETHYL-3-CYCLOPENTENYL KETONE, AND A HALOMETHYL (1,2,2-TRIMETHYL-3-CYCLOPENTENYL) KETONE COMPOUNDOctober 2020September 2022Allow2300NoNo
17045939PROCESS FOR PREPARING 2,6-DIALKYLPHENYLACETIC ACIDSOctober 2020November 2022Allow2511YesNo
17045326Method For Preparing Hexahydrofuro-Furanol Derivative, Intermediate Thereof And Preparation Method ThereofOctober 2020July 2022Abandon2111NoNo
17034030PROCESS FOR THE PREPARATION OF FERRIC CITRATESeptember 2020February 2024Abandon4121NoNo
17032546LIGAND AND METHOD OF MANUFACTURING THE SAME, QUANTUM DOT FILM AND METHOD OF MANUFACTURING THE SAME, AND DISPLAY APPARATUSSeptember 2020August 2022Allow2311YesNo
17040960NOVEL CATIONIC LIPID EXHIBITING IMPROVED INTRACELLULAR DYNAMICSSeptember 2020April 2024Allow4331NoNo
17028689NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES WITH ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOFSeptember 2020August 2022Allow2301NoNo
17040479PIPERAZINE AZASPIRO DERIVATIVESSeptember 2020July 2022Allow2201YesNo
17040295CATALYST COMPOSITIONS AND HYDROFORMYLATION PROCESSESSeptember 2020June 2024Allow4411YesNo
16982842SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAMESeptember 2020September 2023Allow3631NoNo
17021576PROCESS FOR CONTINUOUS ACETIC ACID PRODUCTIONSeptember 2020February 2023Allow2911NoNo
16979976LONG ALPHA-OMEGA DI-FUNCTIONAL LINEAR ETHERSSeptember 2020December 2022Allow2711NoNo
17016095CRYSTALLINE 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE DIHYDRATE, COMPOSITIONS AND METHODS OF USE THEREOFSeptember 2020July 2022Allow2310YesNo
17015988PHOSPHONIUM-BASED ZWITTERIONIC MONOMERS AND POLYMERS, AND COMPOSITIONS AND METHODS THEREOFSeptember 2020November 2022Allow2601YesNo
16978988FRAGRANCE AND FLAVOR MATERIALS DERIVED FROM 1-(4-METHYLCYCLOHEX-1-EN-1-YL)ETHAN-1-ONESeptember 2020January 2023Abandon2801NoNo
17012286PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONSSeptember 2020August 2022Allow2310YesNo
17000529Amphiphilic Diphenyl Ether Compounds Derived from Alpha Olefins or Vinylidene Alpha Olefin DimersAugust 2020December 2022Abandon2711NoNo
16970987PROCESSES FOR THE MANUFACTURE OF SECONDARY FATTY ALCOHOLS, INTERNAL OLEFINS AND INTERNAL OLEFIN SULFONATESAugust 2020March 2023Allow3111NoNo
16970113METHOD FOR PRODUCING TRICYCLO[5.2.1.02,6]DECANE-2-CARBOXYLATEAugust 2020September 2021Allow1310NoNo
16969793DERIVATIVES OF SOBETIROMEAugust 2020October 2022Allow2611YesNo
16944554METHOD OF PRODUCING A 2-((METH)ALLYLOXYMETHYL)ACRYLIC ACID DERIVATIVE, AND 2-((METH)ALLYLOXYMETHYL)ACRYLIC ACID ALKALI METAL SALT POWDERJuly 2020March 2023Allow3121YesNo
16965546PENTAFLUOROSULFANYL-SUBSTITUTED AMIDE DERIVATIVES, PREPARATION METHODS THEREOF AND MEDICAL USES THEREOFJuly 2020May 2022Allow2211NoNo
16937154FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASEJuly 2020June 2021Allow1131NoNo
16933212PROCESS FOR PREPARING AZELAIC ACIDJuly 2020August 2022Allow2511YesNo
16963101C5A RECEPTOR MODULATORSJuly 2020April 2023Allow3321YesNo
16930578DIESTER COMPOUND HAVING A DIMETHYLCYCLOBUTANE RING, A PROCESS FOR PREPARING THE SAME, AND A PROCESS FOR PREPARING DIMETHYLCYCLOBUTANE COMPOUND DERIVED FROM THE DIESTER COMPOUNDJuly 2020February 2022Allow1911YesNo
16962436METHOD FOR SYNTHESIZING BORONATE ESTER COMPOUND, SODIUM SALT OF BORONATE ESTER COMPOUND, AND METHOD FOR SYNTHESIZING THE SAMEJuly 2020December 2022Abandon3011NoNo
16927840MOTUPORAMINE DERIVATIVES AS ANTIMICROBIAL AGENTS AND ANTIBIOTIC ENHANCERS AGAINST RESISTANT GRAM-NEGATIVE BACTERIAJuly 2020June 2023Allow3621YesNo
16910116SUBSTRATE TREATING LIQUIDJune 2020May 2024Abandon4721NoNo
16957550METHOD FOR PRODUCING SEMICARBAZIDE COMPOUNDJune 2020July 2021Allow1320YesNo
16955618METHODS OF MAKING POLYFUNCTIONAL POLYFLUORINATED COMPOUNDSJune 2020December 2022Abandon2911NoNo
16879676NOVEL USESMay 2020May 2022Allow2420NoNo
16764476METHOD FOR PREPARING AMINES FROM CARBONYL COMPOUNDS BY TRANSAMINASE REACTION UNDER SALT PRECIPITATIONMay 2020February 2024Allow4521YesNo
16872466METABOLICALLY STABLE VANILLIN DERIVATIVES FOR THE TREATMENT OF HYPOXIAMay 2020June 2021Allow1311NoNo
16632592GINGEROL DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST BIOFILM FORMATION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING BIOFILM-CAUSED INFECTION SYMPTOMApril 2020February 2024Allow4931NoNo
16858433ALPHA-AMINOAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAMEApril 2020March 2021Allow1111NoNo
16852622METHOD FOR PRODUCING PROSTAGLANDIN DERIVATIVEApril 2020March 2022Allow2301NoNo
16842695PHARMACEUTICAL FORMULATIONSApril 2020August 2024Abandon5350NoYes
16830037METHOD OF SYNTHESIZING (1R,2R)-NITROALCOHOL COMPOUNDMarch 2020January 2023Allow3421NoNo
16828145Preservative-free Treprostinil DevicesMarch 2020December 2021Allow2100YesNo
16827599IMPROVED 1,1-DISUBSTITUTED ETHYLENE PROCESSMarch 2020March 2021Abandon1211NoNo
16826045HYDROXYTYROSOL URSOLIC ACID ESTER WITH ANTIOXIDANT ACTIVITY AND METHODS OF PREPARING THE SAMEMarch 2020March 2021Allow1210NoNo
16823150BIOAVAILABLE POLYAMINESMarch 2020March 2022Allow2411NoNo
16646506PREPARATION METHOD FOR HIGH PURITY RACEMIC ADRENALINEMarch 2020July 2020Allow400YesNo
16645444METHOD FOR PRODUCING LACTIC ACIDMarch 2020January 2023Abandon3501NoNo
16644867NOVEL THERAPEUTICS FOR CENTRAL NERVOUS SYSTEM DISORDERSMarch 2020February 2022Allow2411NoNo
16643962PROCESS AND INTERMEDIATE FOR THE MANUFACTURE OF DIFLUOROACETYL CHLORIDEMarch 2020December 2022Abandon3301NoNo
16807747COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERSMarch 2020April 2021Allow1401YesNo
16643327METHOD FOR PRODUCING BENZOYL FORMIC ACID COMPOUND AND PYRIDAZINE COMPOUNDFebruary 2020April 2022Abandon2601NoNo
167888087-METHYL-3-METHYLENE-7-OCTENAL ACETAL COMPUND AND METHODS FOR PRODUCING ALDEHYDE COMPOUND AND ESTER COMPOUND USING THE SAMEFebruary 2020April 2022Allow2611NoNo
16636955METHOD FOR PREPARING LATANOPROSTENE BUNOD, AND INTERMEDIATE THEREFORFebruary 2020August 2020Allow701NoNo
16635234PROCESS FOR THE PREPARATION OF ELAFIBRANOR AND NOVEL SYNTHESIS INTERMEDIATESJanuary 2020June 2022Allow2811YesNo
16749519PROCESS FOR CONVERTING S-ENANTIOMER TO ITS RACEMIC FORMJanuary 2020November 2021Allow2201NoNo
167396451,3-FATTY DIOL COMPOUNDS AND DERIVATIVES THEREOFJanuary 2020July 2021Allow1810NoNo
16629742Method for Producing Herbicide IntermediateJanuary 2020December 2021Allow2320YesNo
16629427CONVERSION OF POLYSTYRENE TO BENZOIC ACIDJanuary 2020May 2022Abandon2811NoNo
16734824METHOD FOR PREPARING A β -HYDROXYCARBOXYLIC ACID ESTERJanuary 2020April 2021Allow1521YesNo
16627016Process for the Preparation of a Mixture of Chelating Agents, Mixture of Chelating Agents and Methods of Using ThemDecember 2019February 2023Allow3711YesNo
16624318METHOD FOR PRODUCING 3-HYDROXY-3-METHYLBUTYRATE OR SALT THEREOFDecember 2019August 2022Abandon3221NoNo
16624183METHOD FOR PREPARING SUBSTITUTED 4-AMINOINDANE DERIVATIVESDecember 2019August 2021Allow1901YesNo
16618902BIODEGRADABLE DIETHANOLAMINE DERIVATIVE CHELATING AGENT AND PREPARATION PROCESS THEREOFDecember 2019March 2021Abandon1511NoNo
16618597SURFACTANTS FOR THE TREATMENT OF CONDITIONS THROUGH TARGETED NECROSISDecember 2019February 2022Abandon2711NoNo
16617428METHODS OF MAKING OLEFINIC E- AND Z-ISOMERSNovember 2019April 2022Allow2911NoNo
16690298INHIBITORS OF METALLO-BETA-LACTAMASES PRODUCED BY MULTIDRUG-RESISTANT BACTERIANovember 2019February 2022Allow2621YesNo
16613810Catalyst for Catalytic Oxidation of Furfural to Prepare Maleic Acid and Application ThereofNovember 2019October 2021Allow2311YesNo
16611926CRYSTAL FORM AND AMORPHOUS FORM OF DEZOCINE ANALOGUE HYDROCHLORIDENovember 2019January 2022Allow2711YesNo
16665114N-(7-FLUORO-1,1,3-TRIMETHYL -1 H-INDEN-4YL) AMIDES AND A PROCESS FOR PREPARING SAMEOctober 2019August 2021Allow2210NoNo
16608599ELECTROLUMINESCENT MATERIAL, METHOD FOR MANUFACTURING SAME, AND LIGHT EMITTING DEVICEOctober 2019May 2023Abandon4211NoNo
16608592Novel Compositions For Preventing And/Or Treating Degenerative Disorders Of The Central Nervous System And/Or Lysosomal Storage DisordersOctober 2019February 2022Allow2721YesNo
16662517POLYMORPHIC COMPOUNDS AND USES THEREOFOctober 2019January 2022Allow2711YesNo
16607772LIPOPEPTIDE COMPOUNDS FOR THE TREATMENT OF PAIN DISORDERSOctober 2019April 2022Allow3011YesNo
16491105LEONURINE CRYSTAL AND USE THEREOF IN PREPARATION OF INSULIN SENSITIZER, HYPOGLYCEMIC DRUG AND LIPID-LOWERING DRUGOctober 2019May 2022Allow3211YesNo
16605645OPTICALLY-ACTIVE 2-AMINO-PHOSPHONOALKANE ACID, OPTICALLY-ACTIVE 2-AMINOPHOSPHONOALKANE ACID SALT, AND HYDRATES OF THESEOctober 2019September 2021Allow2311YesNo
16598694CRYSTALLINE SOLVATE FORMS OF A PHARMACEUTICALOctober 2019March 2021Allow1710NoNo
16604298LIPID DERIVATIVE FOR NUCLEIC ACID INTRODUCTIONOctober 2019March 2021Allow1701YesNo
16603874Novel Alpha-Hydroxy Carboxylic Acid and Derivatives and Other GRAS-Based Amide and Imide Prodrugs of Amphetamine Compounds and Uses ThereofOctober 2019April 2022Abandon3021NoNo
16603880Novel Alpha-Hydroxy Carboxylic Acid And Derivatives And Other GRAS- Based Prodrugs Of Gamma-Hydroxybutyrate (GHB) And Uses ThereofOctober 2019September 2023Abandon4741NoNo
16499626CHEMICAL PROCESS OF PREPARING DEHYDROHEDIONESeptember 2019October 2021Allow2430YesNo
16498313PROCESS AND SYSTEMS FOR OBTAINING 1,3-BUTANEDIOL FROM FERMENTATION BROTHSSeptember 2019May 2024Abandon5521NoYes
16579545PSYCHOTROPIC AGENTS AND USES THEREOFSeptember 2019February 2022Allow2920YesNo
16496598ALIPHATIC AMINE AND ITS PREPARATION METHOD AND USESeptember 2019November 2021Abandon2601NoNo
16495907Cu- and Ni-Catalyzed Decarboxylative Borylation ReactionsSeptember 2019July 2021Allow2211YesNo
16574335NICKEL DIATOMACEOUS EARTH CATALYST AND METHOD FOR PRODUCING THE SAMESeptember 2019August 2020Allow1110YesNo
16495360Catalytic Process For Synthesizing N,N-Dimethyl Glucamine From N Methyl GlucamineSeptember 2019September 2021Abandon2410NoNo
16492256NOVEL COMPOSITION OF 7,9-DODECADIENYL-1-ACETATE ISOMERS AND PROCESS FOR PRODUCTION THEREOFSeptember 2019January 2023Allow4021YesNo
16490989METHODS FOR FORMING 1,3,5,7-TETRAALKYL-6-(2,4-DIMETHOXYPHENYL)-2,4,8-TRIOXA-6-PHOSPHAADAMANTANESeptember 2019May 2021Allow2011NoNo
16560146BRANCHED ACETAL COALESCING AIDSSeptember 2019March 2022Abandon3011NoNo
16490598METHOD FOR SYNTHESIZING KETOXIMESeptember 2019January 2020Allow510YesNo
16558125PdIn Alloy Catalyst, Method for Manufacturing PdIn Alloy Catalyst and Application ThereofSeptember 2019June 2020Allow911YesNo
16556466ORGANIC SEMICONDUCTING MATERIAL AND ITS SYNTHESIS AND ORGANIC SEMICONDUCTING COMPONENT WITH THE MATERIALAugust 2019December 2021Allow2721YesNo
16557967AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAMEAugust 2019May 2022Allow3221YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MURESAN, ANA Z.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
0
(0.0%)
Examiner Reversed
1
(100.0%)
Reversal Percentile
91.1%
Higher than average

What This Means

With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
9
Allowed After Appeal Filing
2
(22.2%)
Not Allowed After Appeal Filing
7
(77.8%)
Filing Benefit Percentile
30.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 22.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MURESAN, ANA Z - Prosecution Strategy Guide

Executive Summary

Examiner MURESAN, ANA Z works in Art Unit 1622 and has examined 326 patent applications in our dataset. With an allowance rate of 75.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 25 months.

Allowance Patterns

Examiner MURESAN, ANA Z's allowance rate of 75.2% places them in the 42% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by MURESAN, ANA Z receive 1.51 office actions before reaching final disposition. This places the examiner in the 24% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MURESAN, ANA Z is 25 months. This places the examiner in the 77% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +41.4% benefit to allowance rate for applications examined by MURESAN, ANA Z. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 31.3% of applications are subsequently allowed. This success rate is in the 66% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 40.0% of cases where such amendments are filed. This entry rate is in the 62% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 33.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 70.2% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.